94 related articles for article (PubMed ID: 32572939)
1. Trichostatin A alleviates the process of breast carcinoma by downregulating LPAR5.
Zheng YQ; Miao X; Li J; Hu MF; Zhu YS; Li XR; Zhang YJ
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6417-6425. PubMed ID: 32572939
[TBL] [Abstract][Full Text] [Related]
2. LPAR5 stimulates the malignant progression of non-small-cell lung carcinoma by upregulating MLLT11.
Zhang HP; Chen QK; Xu JF
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8902-8910. PubMed ID: 32964980
[TBL] [Abstract][Full Text] [Related]
3. [Expression of ER alpha in chemically induced MDA-MB-435 cells and its responsiveness to endocrine].
Fan J; Lu JS; Yin WJ; Lei W; Wu FY; Wu J; Hou YF; Li DQ; Di GH; Shen ZZ; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):886-9. PubMed ID: 17533736
[TBL] [Abstract][Full Text] [Related]
4. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
5. [Tricostantin A inhibits self-renewal of breast cancer stem cells in vitro].
Peng L; Li FX; Shao WF; Xiong JB
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Oct; 33(10):1421-6. PubMed ID: 24144739
[TBL] [Abstract][Full Text] [Related]
6. Short-term stimulation with histone deacetylase inhibitor trichostatin a induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells without increasing cell invasion ability.
Shen Z; Liao X; Shao Z; Feng M; Yuan J; Wang S; Gan S; Ha Y; He Z; Jie W
BMC Cancer; 2019 Mar; 19(1):262. PubMed ID: 30902084
[TBL] [Abstract][Full Text] [Related]
7. Effects of histone deacetylase inhibitors on regenerative cell responses in human dental pulp cells.
Luo Z; Wang Z; He X; Liu N; Liu B; Sun L; Wang J; Ma F; Duncan H; He W; Cooper P
Int Endod J; 2018 Jul; 51(7):767-778. PubMed ID: 28375564
[TBL] [Abstract][Full Text] [Related]
8. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
[TBL] [Abstract][Full Text] [Related]
9. LPAR5 promotes thyroid carcinoma cell proliferation and migration by activating class IA PI3K catalytic subunit p110β.
Zhao WJ; Zhu LL; Yang WQ; Xu SJ; Chen J; Ding XF; Liang Y; Chen G
Cancer Sci; 2021 Apr; 112(4):1624-1632. PubMed ID: 33540491
[TBL] [Abstract][Full Text] [Related]
10. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway.
Ma X; Yan W; Dai Z; Gao X; Ma Y; Xu Q; Jiang J; Zhang S
Drug Des Devel Ther; 2016; 10():1419-41. PubMed ID: 27143851
[TBL] [Abstract][Full Text] [Related]
11. [Role of histone deacetylase in inhibiting invasion of human gastric carcinoma cell line SGC-7901 by PPARgamma-mediated pathway].
Ma GD; Zhang CQ; Hou J; Zhang LY; Lin C
Ai Zheng; 2009 Jul; 28(7):695-701. PubMed ID: 19624894
[TBL] [Abstract][Full Text] [Related]
12. PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer.
Chen L; Jin T; Zhu K; Piao Y; Quan T; Quan C; Lin Z
Oncotarget; 2017 Feb; 8(7):11937-11949. PubMed ID: 28060760
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.
Li J; Zhang T; Yang F; He Y; Dai F; Gao D; Chen Y; Liu M; Yi Z
Br J Pharmacol; 2015 Aug; 172(15):3817-30. PubMed ID: 25884486
[TBL] [Abstract][Full Text] [Related]
14. [Inhibition of Histone Deacetylases Reverses Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer Cells through a Slug Mediated Mechanism].
Rahimian A; Barati G; Mehrandish R; Mellati AA
Mol Biol (Mosk); 2018; 52(3):474-481. PubMed ID: 29989579
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen.
Scott GK; Marden C; Xu F; Kirk L; Benz CC
Mol Cancer Ther; 2002 Apr; 1(6):385-92. PubMed ID: 12477051
[TBL] [Abstract][Full Text] [Related]
16. Trichostatin A, a histone deacetylase inhibitor suppresses NADPH Oxidase 4-Derived Redox Signalling and Angiogenesis.
Hakami NY; Dusting GJ; Peshavariya HM
J Cell Mol Med; 2016 Oct; 20(10):1932-44. PubMed ID: 27297729
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of all-trans-retinoic acid and trichostatin A on the induction of differentiation of thyroid carcinoma cells.
Yuan GB; Kuang AR; Fan Q; Yu LB; Mi YX
Chin J Cancer; 2010 Apr; 29(4):379-84. PubMed ID: 20346212
[TBL] [Abstract][Full Text] [Related]
18. Trichostatin A, a histone deacetylase inhibitor, reverses epithelial-mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells.
Wang X; Xu J; Wang H; Wu L; Yuan W; Du J; Cai S
Biochem Biophys Res Commun; 2015 Jan; 456(1):320-6. PubMed ID: 25434997
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors alter the expression of molecular markers in breast cancer cells via microRNAs.
Shi Y; Jia Y; Zhao W; Zhou L; Xie X; Tong Z
Int J Mol Med; 2018 Jul; 42(1):435-442. PubMed ID: 29620153
[TBL] [Abstract][Full Text] [Related]
20. TET1 partially mediates HDAC inhibitor-induced suppression of breast cancer invasion.
Lu HG; Zhan W; Yan L; Qin RY; Yan YP; Yang ZJ; Liu GC; Li GQ; Wang HF; Li XL; Li Z; Gao L; Chen GQ
Mol Med Rep; 2014 Nov; 10(5):2595-600. PubMed ID: 25175940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
